Home › Compare › VEGGD vs ABBV
VEGGD yields 20000.00% · ABBV yields 3.06%● Live data
📍 VEGGD pulled ahead of the other in Year 1
Combined, VEGGD + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VEGGD + ABBV for your $10,000?
Better Plant Sciences Inc., through its subsidiaries, develops, markets, and sells plant-based products for health and wellness in Canada and the United States. It offers plant-based beverages consisting of cold-pressed juices, cleanses, and booster shots; plant-based personal care products, including skin care, hair care, body care, and baby care; and plant-based home cleaning products, as well as operates Jusu Bar, a quick serve restaurant under the Jusu brand name. The company also provides mushroom consumer products under the NeonMind brand name; and develops, produces, markets, and distributes various plant-based frozen meals. It offers its products through retail stores and direct to consumer ecommerce platforms. The company was formerly known as The Yield Growth Corp. and changed its name to Better Plant Sciences Inc. in August 2020. Better Plant Sciences Inc. was incorporated in 2014 and is headquartered in Vancouver, Canada.
Full VEGGD Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.